Over 10 million doses of COVID‐19 vaccines based on RNA technology, viral vectors, recombinant protein, and inactivated virus have been administered worldwide. Although generally very safe, post‐vacci...

Applied to samples from more than 600 patients and controls, urinary cell-free RNA profiling with uRARE-seq demonstrated high sensitivity in detecting bladder cancer, and correlated with treatment res...

Metalloproteins are essential to many cellular processes. They use metal ions as cofactors to catalyze reactions, stabilize protein structures, and mediate electron transfer. Identifying their metal-binding sites remains difficult because of the complexity of protein environments and the promiscuous binding of metal ions, and existing computational methods are limited by accuracy and data scarcity. Here we introduce PRIME, a hybrid deep learning framework that combines evolutionary and structural signals to predict metal-binding sites accurately and efficiently. PRIME employs protein language models and pre-trained structure models to extract information from protein sequences and structures, together with a probe generation algorithm that bridges sequence- and structure-based predictions by scanning candidate sites. PRIME outperforms existing methods across diverse metal ions, from abundant zinc and calcium to challenging potassium and sodium. Ablation analysis shows that pretrained s

The gut microbiome is emerging as a modifier of risk for neurodegenerative diseases, but underlying mechanisms remain poorly understood. Here, we show that the hTau.P301S mouse model for progressive tauopathy develops alterations in the composition and function of the gut microbiome that are not recapitulated in amyloid-based 5xFAD or 3xTg models for Alzheimer’s disease. Disrupting the gut microbiome via chronic antibiotic treatment exacerbates cognitive deficits and tau pathology in hTau.P301S mice, demonstrating a causal influence of the microbiome on tau-driven disease progression. This corresponds with widespread alterations in microbiome-dependent metabolites in the sera and brains of hTau.P301S mice, including subsets that correlate with the severity of tau pathology. By screening against tau biosensor cells, we identify select microbial metabolites—trimethylamine-N-oxide, 3-indoxyl sulfate, phenol sulfate, thymidine, and 2’deoxyuridine—that promote tau seeding and aggregation. S

In contrast to RNA from cellular urinary sediments, cfRNA from urinary supernatants is highly fragmented (Extended Data Fig. 1a), suggesting that a sequencing approach optimized for short RNA fragments would be required. We therefore adapted RARE-Seq8, a hybrid capture-based sequencing approach for plasma cfRNA, to analyze urine cfRNA. We compared three extraction strategies and found that a silica column-based approach yielded the highest RNA concentrations (Extended Data Fig. 1b). Urine specific gravity was significantly correlated with RNA yield (R = 0.5, P = 0.0004; Extended Data Fig. 1c), but did not impact gene expression profiles (Extended Data Fig. 1d). RNA yield was inversely associated with urine pH, consistent with lower RNA stability under alkaline conditions (P = 0.002; Extended Data Fig. 1e) but unaffected by storage time at −80 °C (R = −0.0075, P = 0.85; Extended Data Fig. 1f). Two preservative strategies (ethylenediaminetetraacetic acid or a commercial preservative solution) yielded similar RNA concentrations, fragment sizes and gene expression profiles (P = 0.66; Extended Data Fig. 1g,h and Supplementary Table 1). In addition, we observed no significant changes in RNA concentration or transcript abundances after one freeze–thaw cycle (Extended Data Fig. 1i,j). Lastly, to test the stability of urine cfRNA,...

A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose bladder cancer more accurately than current standard methods.

Chinese biotech ​company ‌Abogen said ​on ​Friday it signed ⁠a ​licensing ​and option agreement ​worth ​about $7.8 billion with ‌Swiss ⁠drug maker Novartis ​to ​advance ⁠RNA-based ​therapy.

Chinese biotech ​company ‌Abogen said ​on ​Friday it signed ⁠a ​licensing ​and option agreement ​worth ​about $7.8 billion with ‌Swiss ⁠drug maker Novartis ​to ​advance ⁠RNA-based ​therapy.

UK NICE Backs Arrowhead, Ionis RNA Drugs for Familial Chylomicronaemia Syndrome

Faktencheck: Mimikama entlarvt die Falschmeldung über RNA-Sprays in Lebensmitteln zur heimlichen Impfung als Desinformation und unbegründete Angstmacherei

The Antisense and RNAi Therapeutics Market is emerging as a significant segment of the advanced drug development landscape as pharmaceutical companies increasingly explore RNA-based approaches to target disease-associated genes and proteins. The market was valued at US$ 5.7 billion in 2025 and is expected to reach US$ 22.1 billion by 2034, registering an estimated CAGR of 16.25% during 2026–2034…

No description available

Read the full paper: TurboID-based proximity labeling identifies novel germline proteins that maintain E granule integrity and small RNA homeostasis in C. elegans

RNA modifications play an important role in biological processes. Mapping the diversity of RNA chemistry and studying the biological function of in...

PCR-based measurement of RNA targets in wastewater epidemiology is subject to substantial variation, resulting in considerable uncertainty in disease prevalence estimates.

Scientists at Earlham Institute, John Innes Centre, University of Freiburgh, and University Medical Center Rotterdam present EISCA and EISTA, two standardized, end-to-end pipelines for single-cell RNA- seq and imaging-based spatial transcriptomics analysis.